The European Medicines Agency (EMA) has said it is yet to complete its review of GlaxoSmithKline (GSK) diabetes drug Avandia, amid claims it can lead to increased heart risks.

The EMA’s investigation will be used to determine whether the risk of cardiovascular complications when using Avandia impacts on the drug’s benefit-risk profile.

The review is expected to be finished by September.

GSK has not been without its problems in recent weeks, having posted a quarterly loss of £304m following legal settlements in excess of $1bn in relation to Avandia and other medications, including antidepressant Paxil.